Prostate Cancer
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
September 11, 2023
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
September 11, 2023
A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy.
September 11, 2023
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of 177Lu-PSMA I&T.
September 11, 2023
Application of next-generation imaging in biochemically recurrent prostate cancer.
September 11, 2023
Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
September 8, 2023
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.
September 8, 2023
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
September 8, 2023
Quality rectal hydrogel placement allows for gel-enabled dose-escalated EBRT (GEDE-EBRT) without rectal interference in prostate cancer.
September 7, 2023
State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature.
September 7, 2023
Image-guided radiation therapy produces lower acute and chronic gastrointestinal and genitourinary toxicity in prostate cancer patients.
September 7, 2023
JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy
September 6, 2023